Engraftment was achieved in 43/45 (95%) recipients of peripheral blood stem cells (PBSC) from HLA-compatible unrelated donors (n = 45), compared to all 45 patients in matched controls receiving bone marrow and 14/18 (78%) recipients of CD34-selected PBSC (P Ͻ 0.01). The time to reach ANC Ͼ0.5 × 10 9 /l was a median of 16 days in the PBSC and CD34 groups, compared to 20 days in the bone marrow controls (P Ͻ 0.001 vs PBSC). The time to reach platelets Ͼ50 × 10 9 /l was a median of 23 days in the PBSC group and 24 days in the CD34 group, which was significantly faster than 29 days in the bone marrow controls (P Ͻ 0.01). Acute GVHD grades II-IV developed in 30% in the PBSC group, 20% in the recipients of bone marrow and 18% in the CD34 group. The corresponding figures for chronic GVHD were 59%, 85% and 0% (P Ͻ 0.01) in the three groups, respectively. The probability of non-relapse death was 27% in the recipients of PBSC, 21% in the bone marrow controls and 60% in the CD34 group (NS). The 2-year leukaemia-free survival was 46% in the PBSC group, 41% in the bone marrow group and 25% in the CD34 group (NS). Bone Marrow Transplantation (2000) 25, Suppl. 2, S6-S8.
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2-5 PBSC contains higher numbers of mononuclear cells, especially CD34
+ cells, natural killer cells and T cells, than bone marrow. [5] [6] [7] It was feared that the higher number of T cells would cause more severe GVHD, compared to bone marrow, especially when using PBSC from unrelated donors. We harvested PBSC from an unrelated donor, who was unable to lie on the operation were mobilised after stimulation with G-CSF and given to the recipient. The patient showed prompt engraftment, was discharged from hospital on day 13 after transplantation and had only mild acute GVHD. 8 This experience encouraged us also to use PBSC from unrelated donors. We here report our experience of PBSC from unrelated donors given unmanipulated grafts or CD34-selected cells.
Patients and methods
Among 63 recipients of unrelated PBSC, 17 were from Dresden, 16 from Essen, 16 from Huddinge and 14 were from Idar-Oberstein. Among these, 45 received unmanipulated grafts and 18 CD34 + selected cells using immunomagnetic beads (Isolex 300SA; Baxter, Deerfield, IL, USA). Each patient who received an unmanipulated PBSC was matched for HLA compatibility, diagnosis, disease stage, age, GVHD prophylaxis, with a patient from the same transplant centre who was given bone marrow. Median age in the PBSC group was 35 (range 5-56) years, compared to 34 (9-55) years in the bone marrow controls and 37 (7-56) years in the CD34 group. The diagnoses were AML in 17 patients in the PBSC and bone marrow group, and four in the CD34 group. Among those with ALL, there were five in the PBSC group, six in the bone marrow group and three in the CD34 group. One patient in the PBSC group had lymphoma. There were 21 patients with CML in the PBSC and bone marrow groups, respectively, and nine in the CD34 group. One patient each in the PBSC group and in the bone marrow groups had aspartylglucosaminuria. Two patients in the CD34 group had MDS and one had SAA. The proportions of patients with malignant disease and beyond first remission or first chronic phase were 23 (51%) in the PBSC group, 25 (55%) in the bone marrow group and 11 (61%) in the CD34 group.
Details from this study have been published elsewhere. 7 All donors were HLA-A, -B and -DR␤1-compatible with the recipient, except two minor DR␤1 mismatches. HLAtyping was serological for class I and polymerase chain reaction single-stranded polymorphism (PCR-SSP) for class II. The PBSC donors received G-CSF in a dose ranging from 9 to 12.5 g/kg/day given for 4-6 days. One (n = 29) or two (n = 16) leukaphereses were performed. The donors complained of skeletal pain from G-CSF, but had no other adverse effects.
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Conditioning consisted of cyclophosphamide and total body irradiation, given to 37 patients in the PBSC group and 40 in the bone marrow group. 7 Busulphan (16 mg/kg) combined with cyclophosphamide (200 mg/kg) was given to all patients in the CD34 group, six in the PBSC group and three in the bone marrow group. ATG or OKT3 was given to 19 patients in the PBSC group, 17 in the bone marrow group and 17 in the CD34 group, respectively. Almost all patients were given immunosuppression with cyclosporine, combined with a short course of methotrexate with or without prednisolone. 9 In the CD34 group, eight patients were given cyclosporine alone and three patients received no post-transplant immunosuppression. The patients underwent transplantations between February 1993 and September 1998.
Results
The number of nucleated cells was a median of 8.5 (range 2.7-54.1) × 10 8 /kg in the PBSC group, which was significantly higher than 3.1 (0.2-6.1) in the bone marrow group (P Ͻ 0.001), which was higher than 0.04 (0.02-8.7) in the CD34 group (P Ͻ 0.001). The CD34 content in the corresponding grafts were 6.3 (2.4-16.7) × 10 6 /kg, 3.2 (1.3-10.4) and 3.6 (1.2-11.3) in the three groups, respectively (PBSC vs each of the others, P Ͻ 0.001). The median CD3 + cell content was 314, 25.4 and 0.18 × 10 6 /kg in the three groups, respectively (PBSC vs each of the others, bone marrow group vs CD34-selected, P Ͻ 0.001).
Engraftment occurred in 43/45 (95%) of the patients in the PBSC group, all patients in the bone marrow group and in 14/18 (78%) in the CD34 group (P Ͻ 0.01 vs the bone marrow group). Time to ANC Ͼ0.5 × 10 9 /l was a median of 16 days (range 7-27) in the PBSC group, compared to 20 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) in the bone marrow group (P Ͻ 0.001) and 16 (11-37) in the CD34 group. Time to reach platelets Ͼ50 × 10 9 /l was longer in the bone marrow group, 29 (19-150), compared to the PBSC group, 23 (8-395) and the CD34 group, 24 (11-43) (P Ͻ 0.01). The patients in the CD34 group needed a median of seven (3-39) platelet transfusions, which was significantly fewer than 14 in the bone marrow group (P = 0.01). In the PBSC group, the median number of platelet transfusions was nine with a range from 0 to 144. The median day of discharge was 38 days after transplantation in all three groups.
The cumulative incidence of grades II-IV acute GVHD was 30% in the PBSC group, 20% in the bone marrow group and 18% in the CD34 group (NS). The cumulative incidence of chronic GVHD was 59% in the PBSC group, 85% in the bone marrow group and none in the CD34 group, respectively (P Ͻ 0.004 vs PBSC, P Ͻ 0.001 vs bone marrow).
Cumulative non-relapse death (transplant-related mortality) was 27% in the PBSC group, 21% in the bone marrow group and 60% in the CD34 group (NS). Cumulative incidence of relapse was 34%, 47% and 48% in the three groups, respectively (NS). Survival was 50% in the PBSC group, 45% in the bone marrow and 31% in the CD34 group (NS). The corresponding figures for relapsefree survival were 46%, 41% and 25% in the three groups, respectively (Figure 1 ).
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Discussion
We found that PBSC from HLA-compatible unrelated donors gave a faster engraftment of ANC and platelets, compared to matched patients given bone marrow. This is in line with the experience using PBSC in HLA-identical siblings. 5 The reason for the faster engraftment with PBSC than with bone marrow is probably that there are more nucleated cells and CD34 + cells. 6 In the present study, patients given CD34-selected PBSC also had a faster engraftment, especially regarding platelets, compared to the patients receiving bone marrow, despite an equal CD34 cell dose and a lower nucleated cell dose. The reason for the faster engraftment in the CD34 group is probably because these patients were only rarely given methotrexate, which is known to prolong engraftment, compared to cyclosporine used alone. 10 A randomised study in HLA-identical siblings comparing PBSC with bone marrow showed no difference in time to ANC and platelet engraftment. 4 However, in that study, the CD34 content did not differ significantly in the PBSC grafts, compared to the bone marrow grafts.
Graft failure did not differ between the PBSC group and the controls receiving bone marrow. However, graft failure was more common in the CD34 group than in the other two groups (P Ͻ 0.01) because there is a high cell loss with CD34 selection and these grafts contain an overall low number of nucleated cells and T cells. It is well known that T cell depletion increases the risk of rejection, because there may be a dominance in vivo of recipient T cells.
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Although there are more than 12 times more T cells in the PBSC grafts than in bone marrow grafts in this study, there was no difference in moderate-to-severe acute GVHD between patients receiving PBSC and those receiving bone marrow. This accords with a study in HLA-identical siblings, which showed no correlation between the T cell dose in unmanipulated bone marrow grafts and the risk of moderate-to-severe acute GVHD. 12 In contrast, if T cell depletion of the graft is performed, the T cell dose is of utmost importance for the development of acute GVHD. In HLA-identical siblings, a threshold dose for acute GVHD is estimated to be approximately 5 × 10 5 CD3 + cells/kg. All patients receiving CD34-selected PBSC were given a CD3 cell dose below 0.35 × 10 6 /kg. This is less than the threshold dose estimated in HLA-identical siblings. Only two of the 18 patients receiving CD34-selected PBSC from unrelated donors developed moderate-to-severe acute GVHD. So far, no patient in the CD34 group has developed chronic GVHD, which may be due to the close correlation between acute GVHD and chronic GVHD. 13 The recipients of unrelated unmanipulated PBSC had a high probability of chronic GVHD, 59%, which was not significantly different from the controls receiving unrelated bone marrow (85%, NS). In HLA-identical siblings, some reports suggest that there is an increased risk of chronic GVHD in patients receiving PBSC, compared to bone marrow, although this has not been observed in all studies. 4, 5, 14 Survival, relapse and relapse-free survival did not differ significantly between the recipients of unrelated PBSC, compared with the bone marrow controls, or the patients receiving CD34-selected PBSC. There was a trend towards a higher transplant-related mortality and a lower survival and leukaemia-free survival in patients receiving CD34-selected PBSC, which may be because this group included 61% high-risk patients.
To conclude, recipients of unrelated PBSC had a faster engraftment of ANC and platelets than matched patients receiving bone marrow. However, GVHD, relapse and survival were similar in the two groups.
